Switch theme
Sign up to access all valuation multiples
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
2009
16
Last FY Revenue n/a
LTM EBITDA -$32.5M
$13.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Unity Biotechnology has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$32.5M.
In the most recent fiscal year, Unity Biotechnology achieved revenue of n/a and an EBITDA of -$25.1M.
Unity Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Unity Biotechnology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$32.5M | XXX | -$25.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$28.3M | XXX | -$28.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$25.2M | XXX | -$26.0M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Unity Biotechnology's stock price is $1.
Unity Biotechnology has current market cap of $11.9M, and EV of $13.6M.
See Unity Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.6M | $11.9M | XXX | XXX | XXX | XXX | $-1.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Unity Biotechnology has market cap of $11.9M and EV of $13.6M.
Unity Biotechnology's trades at n/a EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Unity Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Unity Biotechnology has a P/E ratio of -0.5x.
See valuation multiples for Unity Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11.9M | XXX | $11.9M | XXX | XXX | XXX |
| EV (current) | $13.6M | XXX | $13.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUnity Biotechnology's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
Unity Biotechnology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Unity Biotechnology's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Unity Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Unity Biotechnology acquired XXX companies to date.
Last acquisition by Unity Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Unity Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Unity Biotechnology founded? | Unity Biotechnology was founded in 2009. |
| Where is Unity Biotechnology headquartered? | Unity Biotechnology is headquartered in United States of America. |
| How many employees does Unity Biotechnology have? | As of today, Unity Biotechnology has 16 employees. |
| Is Unity Biotechnology publicy listed? | Yes, Unity Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Unity Biotechnology? | Unity Biotechnology trades under UBX ticker. |
| When did Unity Biotechnology go public? | Unity Biotechnology went public in 2018. |
| Who are competitors of Unity Biotechnology? | Similar companies to Unity Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Unity Biotechnology? | Unity Biotechnology's current market cap is $11.9M |
| Is Unity Biotechnology profitable? | Yes, Unity Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Unity Biotechnology? | Unity Biotechnology's last 12 months EBITDA is -$32.5M. |
| What is the current EV/EBITDA multiple of Unity Biotechnology? | Current EBITDA multiple of Unity Biotechnology is -0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
